$IONS News

RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $85

Ionis Pharmaceuticals Doses First Participant In Phase 1-2 ASCEND Study Of Ion337 For Dravet Syndrome, A Neurological Disorder

HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $125

Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $110

Barclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $90

Canaccord Genuity Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $95

Citigroup Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $100

Ionis Pharmaceuticals Affirms FY2026 Sales Guidance of $875.000M-$900.000M vs $893.928M Est

Jefferies Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $90

Needham Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $86

Ionis Pharmaceuticals Completes Enrollment In Pivotal Cohort (Cohort 1) Of REVEAL Phase 3 Reveal Study Of Obudanersen (ION582) Angelman Syndrome; Adult Cohort (Cohort 2) Is Expected To Complete Enrollment In Q3 2026; Topline Data Expected In 2H 2027

Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction - Slideshow

Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction Transcript

Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Raises Price Target to $75

Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk

Leerink Partners Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $129

HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $130

Ionis Pharmaceuticals Announces License Agreement With Recordati For Zilganersen In Alexander Disease In All Countries Outside The US For $30M Upfront Payment

FDA Approves First Treatment Shown To Reduce The Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia

Leerink Partners Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $122